1250
M. A. P. Martins, R. L. Peres, C. P. Frizzo, E. Scapin, D. N. Moreira, G. F. Fiss, N. Zanatta,
and H. G. Bonacorso
Vol 46
dichloro-4-methoxy-3-penten-2-one 1 (2 mmol) in ethanol
(2 mL) at room temperature. The reaction mixture was stirred
at reflux temperature for 24 h. The residue was extracted with
dichloromethane, dried (MgSO4), filtered, and the solvent was
removed under reduced pressure. The crude product 4 was
obtained with good purity, and the solids products 3 and 5–6
were recrystallized from ethanol as solvent.
Synthesis of 5-dichloromethyl-1,2,3-trimethyl pyrazolium
chloride (7). 1,2-dimethylhydrazine dihydrochloride (2 mmol)
and 36% hydrochloric acid (2 mL) were added to a solution of
1,1-dichloro-4-methoxypent-3-en-2-one 1 (2 mmol) in ethanol
(2 mL) at room temperature. The reaction mixture was stirred at
reflux temperature for 24 and the byproducts were extracted with
dichloromethane. The product 7 was obtained in good purity
from the aqueous phase after evaporation of water under vacuum.
(Z) 1,1-Dichloro-4-phenylaminopent-3-en-2-one (2a). C11H11
Cl2NO Mol. Wt.: 244.12 (83%); mp 63–65ꢀC; 1H NMR (200
MHz, CDCl3) d 2.08 (s, 3H, H5), 5.56 (s, 1H, H3), 5.90 (s,
1H, H1), 7.20–7.40 (m, 5H, Ph), 12.32 (s, 1H, NH); 13C NMR
(50 MHz, CDCl3) d 20.1 (C5), 70.3 (C3), 91.0 (C1), 124.9,
126.7, 129.2, 137.3, 165.9 (C4), 184.6 (C2); m/z 243 (Mþ,
31%), 160 (100), 144 (43), 77 (64).
10.8 (CH3), 69.0 (CHCl2), 105.6 (C4), 142.9 (C5), 143.0 (C3);
m/z 164.1 (Mþ, 13%), 149.1 (100), 109.1 (22).
5-Dichloromethyl-3-methyl-1-phenyl-1H-pyrazole (4). C11
H10Cl2N2 Mol. Wt.: 241.12 (68%); oil; 1H NMR (400 MHz,
CDCl3) d 2.35 (s, 3H, CH3), 6.57 (s, 1H, CH), 6.65 (s, 1H,
CHCl2), 7.43–7.52 (m, 5H, Ph); 13C NMR (100 MHz, CDCl3)
d 13.4 (CH3), 61.1 (CHCl2), 107.5 (C4), 125.9, 128.9, 129.4,
138.3, 142.3 (C5), 149.5 (C3); m/z 240 (Mþ, 36%), 205.1 (73),
169.1 (100).
1-Carboxamide-5-dichloromethyl-3-methyl-1H-pyrazole (5).
C6H7Cl2N3O Mol. Wt.: 208.05 (46%); mp 110–111ꢀC; 1H
NMR (400 MHz, DMSO-d6) d 2.22 (s, 3H, CH3), 6.41 (s, 1H,
CH), 7.76 (s, 1H, CHCl2); 13C NMR (100 MHz, DMSO-d6) d
14.2 (CH3), 64.3 (CHCl2), 107.3 (C4), 145.2 (C5), 151.7 (C3),
152.6 [C(O)NH2]; m/z 207 (Mþ, 84%), 191 (38), 161 (62),
133 (100), 115 (85).
1-Carboximidamide-5-dichloromethyl-5-hydroxy-3-methyl-
4,5-dihydro-1H-pyrazole (6). C6H10Cl2N4O Mol. Wt.: 225.08
(58%); mp 68–70ꢀC; 1H NMR (200 MHz, DMSO-d6) d 2.08
(m, 3H, CH3), 3.61 (d, J ¼ 19.6 Hz, 1H, H4a), 3.38 (d, J ¼
19.4 Hz, 1H, H4b), 7.89 (s, 1H, CHCl2), 9.01 (br s, 3H, 3 ꢃ
NH); 13C NMR (50 MHz, DMSO-d6) d 15.7 (CH3), 47.2 (C4),
73.0 (CHCl2), 96.7 (C5), 152.5 (C3), 158.7 [C(NH)NH2].
5-Dichloromethyl-1,2,3-trimethyl pyrazolium chloride
(Z) 4-Benzylamino-1,1-dichloropent-3-en-2-one (2b). C12H13
Cl2NO Mol. Wt.: 258.15 (68%); mp 72–74ꢀC; 1H NMR (200
MHz, CDCl3) d 2.07 (s, 3H, H5), 4.50 (d, J ¼ 5.9 Hz, 2H,
CH2), 5.41 (s, 1H, H3), 5.85 (s, 1H, H1), 7.30–7.40 (m, 5H,
Ph), 11.11 (br s, 1H, NH); 13C NMR (50 MHz, CDCl3) d 19.3
(C5), 47.2 (CH2), 70.4 (C3), 80.7 (C1), 126.8, 127.7, 128.8,
136.3, 168.0 (C4), 183.8 (C2); m/z 257 (Mþ, 24%), 174 (98),
91 (100), 65 (49).
1
(7). C7H11Cl3N2 Mol. Wt.: 229.54 (60%); mp 112–113ꢀC; H
NMR (200 MHz, H2O/C6D6) d 2.73 (s, 3H, CH3), 4.22 (s, 3H,
CH3), 4.34 (s, 3H, CH3), 7.19 (s, 1H, CH), 7.58 (s, 1H,
CHCl2); 13C NMR (50 MHz, H2O/C6D6) d 11.9 (CH3), 34.2
(CH3), 35.4 (CH3), 59.9 (CHCl2), 107.5 (C4), 145.4 (C5),
147.6 (C3); m/z 193 (M–Cl, 59%), 156 (100), 129 (39).
(Z) 1,1-Dichloro-4-(2-hydroxyethylamino)-pent-3-en-2-one
(2c). C7H11Cl2NO2 Mol. Wt.: 212.07 (78%); mp 70–72ꢀC; H
1
Acknowledgments. The authors thank the Conselho Nacional
NMR (200 MHz, CDCl3) d 2.09 (s, 3H, H5), 3.50 (t, J ¼ 5.6 Hz,
2H, CH2), 3.80 (t, J ¼ 5.2 Hz, 2H, CH2), 5.36 (s, 1H, H3), 5.84
(s, 1H, H1), 10.96 (s, 1H, NH); 13C NMR (50 MHz, CDCl3) d
19.6 (C5), 45.7 (CH2), 60.9 (CH2), 70.6 (C3), 89.8 (C1), 168.9
(C4), 183.3 (C2); m/z 211 (Mþ, 15%), 128 (100), 82 (24).
(E) 1,1-Dichloro-4-(pyrrolidin-1-yl)-pent-3-en-2-one (2d).
C9H13Cl2NO Mol. Wt.: 222.11 (60%); mp 112–113ꢀC; 1H
NMR (200 MHz, CDCl3) d 1.94–2.12 (m, 4H, 2 ꢃ CH2), 2.57
(s, 3H, H5), 3.39 (t, J ¼ 6.1 Hz, 2H, CH2), 3.52 (t, J ¼ 5.9
Hz, 2H, CH2), 5.25 (s, 1H, H3), 5.80 (s, 1H, H1); 13C NMR
(50 MHz, CDCl3) d 17.9 (C5), 24.6 (CH2), 24.9 (CH2), 48.5
(CH2), 48.7 (CH2), 72.5 (C3), 87.8 (C1), 164.6 (C4), 182.6
(C2); m/z 221 (Mþ, 25%), 138 (100), 70 (37).
´
de Desenvolvimento Cientıfico e Tecnologico em Pesquisa
(CNPq/PADCT) and the Fundac¸a˜o de Amparo a Pesquisa do
Estado do Rio Grande do Sul (FAPERGS) for financial support.
The fellowships from CNPq, CAPES, and FAPERGS are also
acknowledged.
´
`
REFERENCES AND NOTES
[1] Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter,
J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha,
J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Ander-
son, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt,
C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.;
Isakson, P. C. J Med Chem 1997, 40, 1347.
(E) 1,1-Dichloro-4-(morpholin-4-yl)-pent-3-en-2-one (2e).
1
C7H11Cl2NO Mol. Wt.: 238.11 (85%) Mp 96–98ꢀC; H NMR
[2] Terrett, N. K.; Bell, A. S.; Brown, D.; Ellis, P. Bioorg Med
Chem Lett 1996, 6, 1819.
(CDCl3, 400 MHz): d 2.56 (s, CH3), 3.51 (qua, 2 ꢃ CH2),
3.76 (qua, 2 ꢃ CH2), 5.53 (s, CH), 5.79 (s, CH); 13C NMR
(CDCl3, 100 MHz): d 16.1 (CH3), 46.5 (CH2), 66.1 (CH2),
72.4 (C), 88.7 (CH), 165.9 (CH), 184.4 (C¼¼O); m/z 237 (Mþ,
6%), 154 (100), 55 (33), 96 (22), 174 (12), 126 (7), 202 (5).
Crystallographic data for 2e were deposited at the Cambridge
Crystallographic Data Center (CCDC 649396). Copies of the
data can be obtained, free of charge, on application to CCDC
12 Union Road, Cambridge CB2 1EZ, UK (Fax: 44-1223-
336033 or e-mail: deposit@ccdc.cam.ac.uk).
5-Dichloromethyl-3-methyl-1H-pyrazole (3). C5H6Cl2N2
Mol. Wt.: 165.02 (83%); mp 89–90ꢀC; 1H NMR (400 MHz,
CDCl3) d 2.30 (s, 3H, CH3), 6.28 (s, 1H, CH), 6.74 (s, 1H,
CHCl2), 8.15 (br s, 1H, NH); 13C NMR (100 MHz, CDCl3) d
[3] de Souza, F. R.; Fighera, M. R.; Lima, T. T. F.; de Bas-
tiani, J.; Barcellos, I. B.; Almeida, C. E.; Oliveira, M. R.; Bonacorso,
H. G.; Flores, A. E. Pharm Biochem Behavior 2001, 68, 525.
[4] (a) Milano, J.; Oliveira, S. M.; Rossato, M. F.; Sauzem, P.
D.; Machado, P.; Beck, P.; Zanatta, N.; Martins, M. A. P.; Mello, C.
F.; Rubin, M. A.; J. Ferreira, Bonacorso, H. G. Europ J Pharmacol
2008, 581, 86; (b) Makino, K.; Kim, H. S.; Kurasawa, Y. J Heterocycl
Chem 1998, 35, 489 and references therein.
[5] (a) Norris, T.; Colon-Cruz, R.; Ripin, D. H. B. Org Biomol
Chem 2005, 3, 1844; (b) Bishop, B. C.; Brands, K. M. J.; Gibb, A. D.;
Kennedy, D. J. Synthesis 2004, 43; (c) Miller, R. D.; Reiser, O. J Het-
erocycl Chem 1993, 30, 755.
[6] Colla, A.; Clar, G.; Martins, M. A. P.; Krimmer, S.; Fi-
scher, P. Synthesis 1991, 483.
Journal of Heterocyclic Chemistry
DOI 10.1002/jhet